Effect of Solubility Improvement via Formation of an Amorphous Composite of Indomethacin and Sulindac on Membrane Permeability.

Hatanaka, Yuta; Uchiyama, Hiromasa; Furukawa, Shingo; Takase, Mai; Yamanaka, Shinya; Kadota, Kazunori; Tozuka, Yuichi

Hatanaka, Yuta; Uchiyama, Hiromasa; Furukawa, Shingo; Takase, Mai; Yamanaka, Shinya; Kadota, Kazunori; Tozuka, Yuichi.

Afiliación

Hatanaka Y; Faculty of Pharmacy, Osaka Medical and Pharmaceutical University.
Uchiyama H; Faculty of Pharmacy, Osaka Medical and Pharmaceutical University.
Furukawa S; Division of Applied Sciences, Muroran Institute of Technology.
Takase M; Division of Applied Sciences, Muroran Institute of Technology.
Yamanaka S; Division of Applied Sciences, Muroran Institute of Technology.
Kadota K; Faculty of Pharmacy, Osaka Medical and Pharmaceutical University.
Tozuka Y; Faculty of Pharmacy, Osaka Medical and Pharmaceutical University.

Chem Pharm Bull (Tokyo) ; 71(3): 257-261, 2023.

Article en En | MEDLINE | ID: mdl-36858532

Asunto(s)

Indometacina; Sulindac; 2-Hidroxipropil-beta-Ciclodextrina/química; Permeabilidad de la Membrana Celular; Permeabilidad; Solubilidad; Dodecil Sulfato de Sodio/química

Palabras clave

amorphous composite; indomethacin; permeability; solubility; sulindac

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sulindac / Indometacina Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sulindac / Indometacina Idioma: En Año: 2023 Tipo del documento: Article